Core Scientific, Inc./tx (CORZR) EBITDA Margin (2021 - 2026)

Core Scientific (CORZR) has 6 years of EBITDA Margin data on file, last reported at 269.36% in Q1 2026.

• For the quarter ending Q1 2026, EBITDA Margin fell 21021.0% year-over-year to 269.36%; the trailing twelve-month figure through Mar 2026 stood at 143.48% (down 8402.0% YoY), and the FY2025 full-year result was 76.98%, down 4916.0% from the prior year.
• EBITDA Margin declined to 269.36% in Q1 2026, from 147.28% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 30.8% in Q1 2024 to a low of 637.54% in Q2 2022.
• A 5-year average of 125.85% and a median of 59.15% in 2025 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin sank 65816 bps in 2022 and jumped 64500 bps in 2023, its largest moves.
• Tracing CORZR's EBITDA Margin over 5 years: stood at 524.6% in 2022, then surged by 101 bps to 2.77% in 2023, then plunged by 2585 bps to 68.89% in 2024, then sank by 114 bps to 147.28% in 2025, then tumbled by 83 bps to 269.36% in 2026.
• Business Quant data shows CORZR's EBITDA Margin at 269.36% in Q1 2026, 147.28% in Q4 2025, and 67.56% in Q3 2025.